Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: ##STR00001##
wherein X is absent, CH.sub.2, or C(O); R.sup.1 is H, OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is H, C.sub.1-6 alkyl, —C(O)(C.sub.1-3 alkyl), or —C(O)O(C.sub.1-3 alkyl); R.sup.4 is C.sub.3-10 cycloalkyl, C.sub.6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R.sup.5 groups; and R.sup.5 is OH, CN, NO.sub.2, halo, C.sub.1-3 alkyl, C.sub.1-3 haloalkyl, C.sub.1-3 alkoxy, C.sub.1-3 haloalkoxy, C.sub.3-7 cycloalkyl, amino, C.sub.1-3 alkylamino, or di(C.sub.1-3 alkyl)amino.

Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.

A new family of mononuclear organometallic complexes of a divalent metal bound to sequential tetradentate monoanionic {ONNN}-type ligands, and polymerization of cyclic esters such as lactides utilizing same are provided. Novel tetradentate monoanionic {ONNN}-type ligands usable for forming these complexes are also provided.

A new family of mononuclear organometallic complexes of a divalent metal bound to sequential tetradentate monoanionic {ONNN}-type ligands, and polymerization of cyclic esters such as lactides utilizing same are provided. Novel tetradentate monoanionic {ONNN}-type ligands usable for forming these complexes are also provided.

The present disclosure provides a nitrogen-containing compound, an electronic element and an electronic device, which belongs to the technical field of organic materials. The nitrogen-containing compound has a structure of Chemical Formula 1, wherein R.sub.1 and R.sub.2 are each independently selected from hydrogen or a group represented by Chemical Formula 1-1, and one and only one of R.sub.1 and R.sub.2 has the group of Chemical Formula 1-1; when R.sub.1 or R.sub.2 is selected from hydrogen, said R.sub.1 and R.sub.2 may be replaced by R.sub.4. The nitrogen-containing compound can improve the performance of electronic elements. ##STR00001##

The present disclosure provides a nitrogen-containing compound, an electronic element and an electronic device, which belongs to the technical field of organic materials. The nitrogen-containing compound has a structure of Chemical Formula 1, wherein R.sub.1 and R.sub.2 are each independently selected from hydrogen or a group represented by Chemical Formula 1-1, and one and only one of R.sub.1 and R.sub.2 has the group of Chemical Formula 1-1; when R.sub.1 or R.sub.2 is selected from hydrogen, said R.sub.1 and R.sub.2 may be replaced by R.sub.4. The nitrogen-containing compound can improve the performance of electronic elements. ##STR00001##

Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same.

Phenoxy acetic acids and phenyl propionic acids and their use in improving mitochondrial energy output in a subject are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same.

The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.

The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.